Market closed
Regulus Therapeutics Inc./$RGLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Ticker
$RGLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
34
ISIN
US75915K3095
Website
RGLS Metrics
BasicAdvanced
$543M
-
-$0.72
0.50
-
Price and volume
Market cap
$543M
Beta
0.5
52-week high
$8.20
52-week low
$1.22
Average daily volume
2.3M
Financial strength
Current ratio
16.305
Quick ratio
14.866
Long term debt to equity
2.03
Total debt to equity
2.03
Interest coverage (TTM)
-295.73%
Management effectiveness
Return on assets (TTM)
-34.23%
Return on equity (TTM)
-53.82%
Valuation
Price to book
7.54
Price to tangible book (TTM)
7.54
Price to free cash flow (TTM)
-11.815
Growth
Earnings per share change (TTM)
-49.42%
3-year earnings per share growth (CAGR)
-35.99%
RGLS News
AllArticlesVideos
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
Business Wire·2 weeks ago
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·2 weeks ago
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Regulus Therapeutics Inc. stock?
Regulus Therapeutics Inc. (RGLS) has a market cap of $543M as of May 16, 2025.
What is the P/E ratio for Regulus Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Regulus Therapeutics Inc. (RGLS) stock is 0 as of May 16, 2025.
Does Regulus Therapeutics Inc. stock pay dividends?
No, Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Regulus Therapeutics Inc. dividend payment date?
Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. (RGLS) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.